AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28055065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567
Study 28055065 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d)
Number of subjects: 567
Study 26094361 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic toothbrush
Number of subjects: 26
Study 26094361 — intervention group
Group type: COMPARATOR
Intervention: Triple-headed toothbrush
Number of subjects: 26
Study 26094361 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined brushing with single-tufted toothbrush
Number of subjects: 26
Study 23931935 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mU abobotulinumtoxinA
Number of subjects: 8
Study 23931935 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 8
Study 21574032 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddling
Number of subjects: 85
Study 19739698 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (Suboxone)
Number of subjects: 0
Study 19739698 — intervention group
Group type: EXPERIMENTAL
Intervention: Less frequent dispensing of buprenorphine/naloxone (thrice weekly)
Number of subjects: 0
Study 19739698 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 0
Study 16328475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu laryngeal mask (ALM)
Number of subjects: 60
Study 16328475 — intervention group
Group type: COMPARATOR
Intervention: LMA‐Classic (LMA)
Number of subjects: 60
Study 14687691 — intervention group
Group type: EXPERIMENTAL
Intervention: Immucytal (one tablet daily in the morning for 8 days per month for three consecutive months)
Number of subjects: 72
Study 14687691 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one tablet daily in the morning for 8 days per month for three consecutive months)
Number of subjects: 72
Study 12212256 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional chordal reconstruction
Number of subjects: 57
Study 12212256 — intervention group
Group type: EXPERIMENTAL
Intervention: Chordal replacement using expanded polytetrafluorethylene (e‐PTFE) sutures and artificial ring valvuloplasty reconstruction
Number of subjects: 57
Study 12212256 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement
Number of subjects: 57
Study 9070549 — intervention group
Group type: EXPERIMENTAL
Intervention: saruplase (80 mg/hour, n = 236)
Number of subjects: 473
Study 9070549 — intervention group
Group type: COMPARATOR
Intervention: alteplase (100 mg every 3 hours, n = 237)
Number of subjects: 473
Study 9070549 — intervention group
Group type: EXPERIMENTAL
Intervention: saruplase
Number of subjects: 473
Study 9070549 — intervention group
Group type: COMPARATOR
Intervention: alteplase
Number of subjects: 473
Study 9070549 — intervention group
Group type: EXPERIMENTAL
Intervention: saruplase and alteplase
Number of subjects: 473
Study 8438616 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 2 x 10(9) live bacteria
Number of subjects: 30
Study 8438616 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses every other day of 2 x 10(9) live bacteria
Number of subjects: 30
Study 8438616 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of 2 x 10(9) live bacteria after 6 months
Number of subjects: 30
Study 3025928 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (a competitive opiate receptor antagonist)
Number of subjects: 12
Study 30132108 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-speed centrifugation (800 r/min)
Number of subjects: 100
Study 30132108 — intervention group
Group type: COMPARATOR
Intervention: Sedimentation (15 min)
Number of subjects: 100
Study 28797829 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week internet intervention (Deprexis) plus usual care
Number of subjects: 1013
Study 28797829 — intervention group
Group type: COMPARATOR
Intervention: Care as usual alone
Number of subjects: 1013
Study 26637080 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative feeding (oral clear fluids began up to six hours after surgery followed by solid foods as tolerated)
Number of subjects: 119
Study 26637080 — intervention group
Group type: COMPARATOR
Intervention: Delayed postoperative feeding (clear fluids began on the first postoperative day and solid foods on the second or third day as tolerated)
Number of subjects: 119
Study 23239679 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken noodle soup (355 ml)
Number of subjects: 9
Study 23239679 — intervention group
Group type: COMPARATOR
Intervention: Water (355 ml)
Number of subjects: 9
Study 21676280 — intervention group
Group type: EXPERIMENTAL
Intervention: HFHC meal (14,644 kJ/d; 3500 kcal/d)
Number of subjects: 10
Study 21676280 — intervention group
Group type: COMPARATOR
Intervention: Dietary Reference Intake (10878.4 kJ/d; 2600 kcal/d)
Number of subjects: 10
Study 18178494 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC640 (640 microg/day)
Number of subjects: 680
Study 18178494 — intervention group
Group type: COMPARATOR
Intervention: CIC160 (160 microg/day)
Number of subjects: 680
Study 16411983 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day (increased to 10 mg/day after 4 weeks)
Number of subjects: 12
Study 16411983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16411983 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 12
Study 16411983 — intervention group
Group type: COMPARATOR
Intervention: Donepezil and Placebo
Number of subjects: 12
Study 12921494 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 5mg
Number of subjects: 1093
Study 12921494 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 2.5mg
Number of subjects: 1093
Study 12921494 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 1mg
Number of subjects: 1093
Study 12921494 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 0.5mg
Number of subjects: 1093
Study 12585821 — intervention group
Group type: EXPERIMENTAL
Intervention: computer treatment
Number of subjects: 10
Study 12585821 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 10
Study 9702935 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 360
Study 9702935 — intervention group
Group type: COMPARATOR
Intervention: Felodipine ER
Number of subjects: 360
Study 7859632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisei women with IGT at baseline
Number of subjects: 0
Study 7859632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisei men with IGT at baseline
Number of subjects: 0
Study 7859632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisei women
Number of subjects: 0
Study 7859632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisei men
Number of subjects: 0
Study 7859632 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese Americans with IGT and NIDD
Number of subjects: 0
Study 7859632 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDD
Number of subjects: 0
Study 2690065 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0
Study 31079082 — intervention group
Group type: EXPERIMENTAL
Intervention: VMSCC service (usual care plus access to a tablet with 30 videos, monthly communication with a registered nurse, regular blood pressure monitoring)
Number of subjects: 384
Study 31079082 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 384
Study 31079082 — intervention group
Group type: EXPERIMENTAL
Intervention: VMSCC service
Number of subjects: 384
Study 28591387 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual atropine sulfate
Number of subjects: 25
Study 25855680 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNERGY stent
Number of subjects: 1684
Study 25855680 — intervention group
Group type: COMPARATOR
Intervention: PROMUS Element Plus stent
Number of subjects: 1684
Study 23726334 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth sealant polish (Biscover LV; Bisco, Schaumberg, Ill) applied to maxillary anterior teeth
Number of subjects: 62
Study 23726334 — intervention group
Group type: COMPARATOR
Intervention: No sealant applied to control teeth
Number of subjects: 62
Study 21875518 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve mobilization exercises
Number of subjects: 28
Study 21875518 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (physiotherapy and supportive inserts)
Number of subjects: 28
Study 19623187 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention including nutrition, physical education (PE), and behavior changes with promotional and educational materials.
Number of subjects: 0
Study 19623187 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 17416111 — intervention group
Group type: EXPERIMENTAL
Intervention: AVI-005 (0.5, 1.66 or 5 million international units, MIU)
Number of subjects: 28
Study 17416111 — intervention group
Group type: EXPERIMENTAL
Intervention: AVI-005
Number of subjects: 28
Study 17416111 — intervention group
Group type: COMPARATOR
Intervention: Control (5 MIU of unglycosylated IFN‐alpha2b)
Number of subjects: 28
Study 17416111 — intervention group
Group type: EXPERIMENTAL
Intervention: AVI-005 and Control
Number of subjects: 28
Study 15258011 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% Mitomycin C (MMC) for 5 minutes
Number of subjects: 114
Study 15258011 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal Conjunctival Autograft (LCAU)
Number of subjects: 114
Study 11533345 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/d for 3 days, 0.25 mg/kg/d for 3 days, 0.10 mg/kg/d for 3 days, 0.05 mg/kg/d for 3 days)
Number of subjects: 542
Study 11533345 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 542
Study 9603589 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleromyography (AMG)
Number of subjects: 28
Study 9603589 — intervention group
Group type: COMPARATOR
Intervention: Electromyography (EMG)
Number of subjects: 28
Study 9603589 — intervention group
Group type: COMPARATOR
Intervention: Xenon anesthesia
Number of subjects: 28
Study 9603589 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 28
Study 7817356 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril 10 mg
Number of subjects: 814
Study 7817356 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril 20 mg
Number of subjects: 814
Study 7817356 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril 10 mg plus hydrochlorothiazide 12.5 mg
Number of subjects: 814
Study 7817356 — intervention group
Group type: COMPARATOR
Intervention: Previous therapy (not specified)
Number of subjects: 814
Study 29497948 — intervention group
Group type: EXPERIMENTAL
Intervention: Left nasal obstruction (right nostril dominant respiration)
Number of subjects: 21
Study 29497948 — intervention group
Group type: EXPERIMENTAL
Intervention: Right nasal obstruction (left nostril dominant respiration)
Number of subjects: 21
Study 29497948 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep (no obstruction)
Number of subjects: 21
Study 27449771 — intervention group
Group type: EXPERIMENTAL
Intervention: PC patients with germline CDKN2A mutations
Number of subjects: 66
Study 27449771 — intervention group
Group type: EXPERIMENTAL
Intervention: PC patients without germline CDKN2A mutations
Number of subjects: 66
Study 27449771 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PC patients
Number of subjects: 66
Study 27449771 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 27449771 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKN2A− PC patients with family history of digestive system tumors
Number of subjects: 66
Study 27449771 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKN2A+ PC patients
Number of subjects: 66
Study 27449771 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKN2A− PC patients
Number of subjects: 66
Study 24932624 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid spray
Number of subjects: 40
Study 24932624 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 40
Study 23557500 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free 0.9% sodium chloride solution
Number of subjects: 359
Study 23557500 — intervention group
Group type: COMPARATOR
Intervention: Heparin saline solution (10 U/mL)
Number of subjects: 359
Study 19674282 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a 180 microg/week plus ribavirin 1000-1200 mg/day
Number of subjects: 1550
Study 19674282 — intervention group
Group type: EXPERIMENTAL
Intervention: mean on-treatment ribavirin dose >13 mg/kg/day
Number of subjects: 1550
Study 19674282 — intervention group
Group type: EXPERIMENTAL
Intervention: baseline factors (serum HCV RNA <= 400,000 IU/mL, alanine aminotransferase >3 x ULN, non-cirrhotic status, age <= 40 years, white non-Latino ethnicity, body mass index <= 27 kg/m(2))
Number of subjects: 1550
Study 19674282 — intervention group
Group type: EXPERIMENTAL
Intervention: cEVR
Number of subjects: 1550
Study 19382402 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.5% ropivacaine
Number of subjects: 90
Study 19382402 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.75% ropivacaine
Number of subjects: 90
Study 19382402 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 1% ropivacaine
Number of subjects: 90
Study 16015455 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger imagery induction
Number of subjects: 80
Study 16015455 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontrollable stress
Number of subjects: 80
Study 16015455 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation imagery induction
Number of subjects: 80
Study 12525509 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 796
Study 12525509 — intervention group
Group type: COMPARATOR
Intervention: Demographic variables
Number of subjects: 796
Study 12525509 — intervention group
Group type: COMPARATOR
Intervention: Mediators of cessation
Number of subjects: 796
Study 12525509 — intervention group
Group type: COMPARATOR
Intervention: Psychological support
Number of subjects: 796
Study 10026388 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptastigmine
Number of subjects: 176
Study 10026388 — intervention group
Group type: COMPARATOR
Intervention: Historical untreated controls
Number of subjects: 176
Study 8660037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent prophylaxis (diazepam at fever)
Number of subjects: 289
Study 8660037 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (diazepam at seizures)
Number of subjects: 289
Study 1905630 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet (LPD)
Number of subjects: 10
Study 1905630 — intervention group
Group type: COMPARATOR
Intervention: Normal protein intake (NPD)
Number of subjects: 10
Study 1905630 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (LPD and NPD)
Number of subjects: 10
Study 6309116 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendly visitors (FV) and biannual nursing visits
Number of subjects: 142
Study 6309116 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual nursing (RN) visits only
Number of subjects: 142
Study 6309116 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 142
Study 29880563 — intervention group
Group type: EXPERIMENTAL
Intervention: Group self‐management course and usual care
Number of subjects: 703
Study 29880563 — intervention group
Group type: COMPARATOR
Intervention: Relaxation and usual care
Number of subjects: 703
Study 27770454 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative total parenteral nutrition (group A; n = 74)
Number of subjects: 157
Study 27770454 — intervention group
Group type: COMPARATOR
Intervention: Oral nutrition alone (group B; n = 83)
Number of subjects: 157
Study 25856933 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DMARDs (Methotrexate 15 mg daily and Sulfasalazine 2 gm daily for 3 months) with Intra‐articular Triamcinolone acetate (40 mg per ml) injections
Number of subjects: 50
Study 25856933 — intervention group
Group type: COMPARATOR
Intervention: DMARDs (Methotrexate 15 mg daily and Sulfasalazine 2 gm daily for 3 months) alone
Number of subjects: 50
Study 25856933 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DMARDs with Intra‐articular corticosteroids
Number of subjects: 50
Study 22286314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 211
Study 22286314 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant 250 mg
Number of subjects: 211
Study 20150396 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuo-proprioceptive training
Number of subjects: 40
Study 18327367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular Hylan G‐F 20 treatment for 3 weeks
Number of subjects: 60
Study 18327367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular Hylan G‐F 20 treatment plus oral vitamin E for 3 weeks
Number of subjects: 60
Study 18327367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular Na‐hyaluronate treatment for 5 weeks
Number of subjects: 60
Study 18327367 — intervention group
Group type: COMPARATOR
Intervention: Only arthroscopy treatment
Number of subjects: 60
Study 15681100 — intervention group
Group type: COMPARATOR
Intervention: Control diet A (1.0 x 1/6 of BEE calories)
Number of subjects: 8
Study 15681100 — intervention group
Group type: COMPARATOR
Intervention: Control diet B (1.5 x 1/6 of BEE calories)
Number of subjects: 8
Study 15681100 — intervention group
Group type: COMPARATOR
Intervention: Control diet C (2.0 x 1/6 of BEE calories)
Number of subjects: 8
Study 15681100 — intervention group
Group type: EXPERIMENTAL
Intervention: SBS patients
Number of subjects: 8
Study 12441905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonized autohaemotransfusion
Number of subjects: 20
Study 10364642 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE genotype
Number of subjects: 0
Study 10364642 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 7723645 — intervention group
Group type: COMPARATOR
Intervention: Cadence at 50, 65, 80, 95, 110 rpm and preferred cadence (85.2 +/- 9.2 rpm for cyclists, 91.6 +/- 10.5 rpm for noncyclists)
Number of subjects: 16
Study 7723645 — intervention group
Group type: COMPARATOR
Intervention: Cadence at 50, 65, 80, 95, 110 rpm and preferred cadence
Number of subjects: 16
Study 7723645 — intervention group
Group type: COMPARATOR
Intervention: Preferred cadence
Number of subjects: 16
Study 2045255 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental splenectomy and extraperitoneal splenic transposition with gastroesophageal devascularization (S.S.S.T.)
Number of subjects: 30
Study 2045255 — intervention group
Group type: COMPARATOR
Intervention: Splenectomy and gastroesophageal devascularization
Number of subjects: 30
Study 6109990 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine 40 mg
Number of subjects: 0
Study 6109990 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine 80 mg
Number of subjects: 0
Study 6109990 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 mg
Number of subjects: 0
Study 6109990 — intervention group
Group type: COMPARATOR
Intervention: Isoprenaline
Number of subjects: 0
Study 30617093 — intervention group
Group type: COMPARATOR
Intervention: Benapenem for injection at doses of 62.5, 125, 250, 500, 1,000, 2,000, or 3,000 mg (part A)
Number of subjects: 142
Study 30617093 — intervention group
Group type: EXPERIMENTAL
Intervention: Benapenem for injection at doses of 250, 500, or 1,000 mg (part B)
Number of subjects: 142
Study 30617093 — intervention group
Group type: EXPERIMENTAL
Intervention: Benapenem for injection at doses of 250, 500, or 1,000 mg once daily for 7 consecutive days (part C)
Number of subjects: 142
Study 29945735 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation with recruitment maneuver (positive end-expiratory pressure of 15 cm H2O and 20 cm H2O for 2 minutes each)
Number of subjects: 34
Study 29945735 — intervention group
Group type: COMPARATOR
Intervention: Control group (noninvasive ventilation with positive end-expiratory pressure of 8 cm H2O)
Number of subjects: 34
Study 26765325 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 927
Study 26765325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study 25436841 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 138
Study 25436841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 22574571 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiletto needle stimulation combined with massage
Number of subjects: 100
Study 22574571 — intervention group
Group type: COMPARATOR
Intervention: Massage therapy alone (control group)
Number of subjects: 100
Study 20222884 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) treatment with two injections, 6 months apart in the gastrocnemius muscle
Number of subjects: 15
Study 20222884 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily stretching programme only)
Number of subjects: 15
Study 20222884 — intervention group
Group type: COMPARATOR
Intervention: Gait analysis, GMFM‐66, or PEDI
Number of subjects: 15
Study 18312522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg x kg(‐1)
Number of subjects: 75
Study 18312522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg x kg(‐1)
Number of subjects: 75
Study 18312522 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (group S)
Number of subjects: 75
Study 15946418 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of tea catechins (224 mg)
Number of subjects: 9
Study 15946418 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of tea catechins (674 mg)
Number of subjects: 9
Study 15946418 — intervention group
Group type: COMPARATOR
Intervention: Control (10 mg of tea catechins)
Number of subjects: 9
Study 12713551 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glycolic acid (pH 3.5), applied once daily, 6 days per week for 4 weeks
Number of subjects: 29
Study 12713551 — intervention group
Group type: COMPARATOR
Intervention: Placebo, applied once daily, 6 days per week for 4 weeks
Number of subjects: 29
Study 10888287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 24
Study 10888287 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrins plus aspartame
Number of subjects: 24